This was an all-time high year for Orion, for both net sales and operating profit.
And welcome on my behalf as well. I'll start with Q4 and some highlights during the last three months of last year.
It's my pleasure to say that all our business divisions had a strong quarter and performed extremely well.
Also, we received a 180 million sales milestone from Bayer related to Nubeqa, and we were able to proceed with our clinical pipeline by initiating a Phase 2 program with ODM-212, a molecule in our oncology pipeline, while our partner Tenax in the United States also initiated a Phase 3 trial called LEVEL-2 with levosimendan for pulmonary hypertension. And Q4. Highlights.
Compared to the previous year, the base business during Q4 grew 18.5% (and 60% including the previously mentioned milestone), while operating profit grew 59% (and 254% including the milestone), bringing us to a 47% operating profit margin in Q4; operating cash flow per share was slightly lower than the previous year, mainly due to the timing of royalty payments from Bayer.
The net sales bridge is almost masked by Nubeqa and Innovative Medicines, as it includes the 180 million milestone, but it doesn't shadow the extremely, extremely good performance of other divisions, Branded Generics and Animal Health. Of course, the divisions are smaller, so the growth in euros is also smaller. And this all resulted in €695 million in net sales during Q4.
Regarding the operating profit.
We, of course, see the 180 million, but a very good development on our royalties, close to 50 million, and also sales volumes brought us €28 million. Price development costs and product mix put us slightly down by 12 million, and the effect of exchange rate on gross margin was 4.1 million, and other operating costs and fixed costs were also well handled. So no, nothing specific there. And so our Q4 operating profit was 328 million.
And now I move to 2025.
This was an all-time high year for Orion Pharma, both with net sales and operating profit. And I want to take the opportunity here today to thank all my colleagues all around the world in Orion Pharma for this achievement. Overall, this involved all business divisions, R&D, and operations. You couldn't achieve anything like this without a very, very good collaboration in the company.
So, in addition to euros, we also had numerous positive developments in R&D, including ARASTEP approvals both in Europe and the US.
Several new license and collaboration agreements were established, including license agreements for early-stage technology platforms in our innovative medicines and oncology, but also acquiring and in-licensing product rights for both branded products and generics. Also, MSD, our other significant partner, expanded the Opevesostat development to women's cancers, which is wonderful news both for women suffering from these cancers and for taking all the possible opportunities of this molecular mechanism of action. The Board of Directors of Orion Corporation is proposing a dividend of €1.8 per share, and this is proposed to be paid in two installments.
For the full year, our base business achieved 21% growth, with total growth reaching 22.5% including milestones; operating profit for the base business increased by 58% (or 59% if rounded), and by 52% including milestones, which impacts the full-year operating profit margin. This brings us to 33.4% compared to the previous year's 27%. And of course, this is mainly, or partly, due to the milestone that we received. Operating cash flow was slightly better than in 2024, driven mainly by sales performance, as the milestone will be visible in the cash flow only this year.
And now I move to the divisions.
For Innovative Medicines, net sales are primarily from Nubeqa, comprising both royalties and product sales. The dark part here describes the sales and royalties, where the growth was close to 38%. Of course, with the milestone also included, this brings us to 152% growth. And then, for the full year, the growth was 60% for the base business and 55% with the milestone.
And then there is the picture that we always want to have here to remind you of the very back-end loaded character of this business due to the tiered royalties from Bayer, and we can see it extremely well here in Q4 2025, where the royalties jump up significantly from the previous quarter. The product deliveries and product sales between Q3 and Q4 last year remained at a similar level. Branded Products continued.
In Q4, the double-digit growth was 11%, and the full year growth was close to 10%. For the respiratory portfolio. The growth comes from the budesonide formoterol combination product for the CNS. It comes from Stalevo or the Entacapone product family for Parkinson's disease, and especially retaining the rights in Japan back to Orion Pharma, but also from some new products that we've been launching in Europe and then a significant growth of our women's Health portfolio.
Generics and Consumer Health achieved strong results last year. 5.7% growth during Q4 is above all averages in this business, and 4.6% for the full year as well. And this is a result of a lot of activities.
We've done more launches than ever in our current territories. We've had some bigger launches this year for products whose patents have ended. And this comes also from all of our regions.
Animal Health Q4 was more subdued compared to the previous quarters, with only 1% growth. And this is mainly when you see these types of changes on a quarterly basis. In Animal Health, it's usually the delivery timing of products to our partners. However, it didn't have a big effect on the full year sales, where the growth is close to 10%.
And in a similar way to generics, the growth truly comes from a broad geographic region globally, as well as from a broad portfolio covering both livestock and companion animal businesses.
This is a nice list of our ten biggest products. Almost all products are growing, some even with very healthy two-digit numbers, while others are more or less at par, like Animal Health, Dexdomitor, and Burana. It is worth noting that the Divina series. The Women's Health portfolio has now climbed to be the number four, so it has actually now climbed past the Animal Health sedative portfolio.
And this is a very natural order of products here, with the innovative product Nubeqa as the first and fastest-growing product.
And then the three main branded products follow. And then we have the biggest generic products represented here. Simdax. Unfortunately, of course, Fareston's decline is again a matter of delivery timing.
I think the big message in this slide is that, to my recollection, this is the first year when Innovative Medicines is our biggest division.
So this is clearly a kind of a landmark event for Orion. Generics still generate almost 30% of our net sales, and Branded Products contribute 17%. And the two other divisions, Animal Health and Fermion, are significantly smaller ones. Regarding our key clinical development. Pipeline. I already mentioned that we've started Phase 2 for ODM-212 in two different indications, including mesothelioma, both of which are rare oncology indications. We were able to start this study already at the end of last year, and are aiming to start a study with the combination of this molecule with some current oncology treatments during the first part of this year. And also you can see here now two studies for Levosimendan, also the LEVEL-2. And this is a very nice slide on sustainability. This time about diversity. Orion has been ranked as number three in the Nordic Business Diversity Index, which means that if you look at the numbers here on this slide, you can see how men and women are represented. What is the share of men and women on different levels of the organization?
You can look at the board of directors, where almost 40% of members are women. Almost 45% of the members are women. And if you look at the whole personnel in Orion Pharma, almost 56% of the personnel are women.
And there is a lot of other information here of which we are very, very proud. One that I can mention is the accomplishment of the Code of Conduct Agreements with our suppliers, which is 98%.
We provided our outlook for 2026 already on January 14th, and it holds. So we've stated that our net sales range for this year is 1.9 billion. 1.9 billion to 2.1 billion, and our operating profit range is 550 million to 750 million. And here are our upcoming events and our general meeting.
Annual General Meeting will be held on 24th of March. I thank you for your attention at this point and we are ready for your questions.